TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34297797
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of IGF-1 to old mice
Study: 34297797
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of anti-TNF-α antibodies to human patients
Study: 34298376
Drug: Recommended treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended treatments (R-T) for first-line (1L) patients
Study: 34298376
Drug: Non-recommended treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-recommended treatments (NR-T) for first-line (1L) patients
Study: 34298376
Drug: Recommended treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended treatments (R-T) for pre-treated (2L+) patients
Study: 34298376
Drug: Non-recommended treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-recommended treatments (NR-T) for pre-treated (2L+) patients
Study: 34301808
Drug: Pacmilimab 10
Normalized name: Pacmilimab
DrugBank: Pacmilimab (DB18873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacmilimab 10 mg/kg + Ipilimumab 3 mg/kg administered every 3 weeks
Study: 34301809
Drug: Pacmilimab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacmilimab at a recommended phase 2 dose (RP2D) of 10 mg/kg administered intravenously every 14 days
Study: 34301809
Drug: Pacmilimab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacmilimab at RP2D of 10 mg/kg
Study: 34302290
Drug: Ceftazidime 40
Normalized name: CEFTAZIDIME 40ML/ML INJ,50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 40 mg/kg IV q6h (max 8 g/day)
Study: 34302533
Drug: Imatinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib monotherapy
Study: 34302589
Drug: Eribulin 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin 1.4 mg/m² in combination with trastuzumab and pertuzumab (HP)
Study: 34302589
Drug: Eribulin 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin 1.4 mg/m²
Study: 34302760
Drug: Bictegravir, emtricitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir, emtricitabine, and tenofovir alafenamide (single-tablet regimen)
Study: 34302788
Drug: Polyomavirus-specific T
Normalized name: Allogeneic JC polyomavirus-specific T-cell therapy
DrugBank: CE-VST01-JC (DB17190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyomavirus-specific T cells infusion
Study: 34304968
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day for up to 3 years, in addition to ongoing corticosteroid treatment.
Study: 34304968
Drug: Tamoxifen treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment.
Study: 34305948
Drug: GC5107 (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC5107 (10% intravenous immunoglobulin) administered at doses ranging from 319 to 881 mg/kg body weight every 21 or 28 days
Study: 34305948
Drug: GC5107 (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC5107 (10% intravenous immunoglobulin)
Study: 34306227
Drug: Tobacco cessation
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco cessation treatment (prescription for nicotine replacement therapy and referral to the quitline)
Study: 34307126
Drug: Neoadjuvant pegylated
Normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pegylated liposomal doxorubicin (PLD) 35 mg/m²
Study: 34307246
Drug: Initial steroid
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial steroid treatment, dosage and duration not specified
Study: 34307504
Drug: Plasma Purification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma Purification Treatment
Study: 34308309
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg DHA per day
Study: 34308309
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg DHA per day
Study: 34309636
Drug: Nilotinib 230
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 230 mg/m2 twice daily
Study: 34309846
Drug: Cam-FOLFOX4 (Camrelizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cam-FOLFOX4 (Camrelizumab 3 mg/kg iv drip injection every 2 weeks plus FOLFOX4)
Study: 34309846
Drug: Cam-GEMOX (Camrelizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cam-GEMOX (Camrelizumab 3 mg/kg iv drip injection every 2 weeks plus GEMOX)
Study: 34310027
Drug: Risk-prediction score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-prediction score based on chemotherapy intensity, time since diagnosis, and type of malignancy.
Study: 34310027
Drug: Intermittent antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent antibiotic prophylaxis (4.3 months to prevent one FN with bacteremia, 5.2 months to prevent one FN with SRE).
Study: 34310436
Drug: Biochemical resolution
Normalized name: Revolution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biochemical resolution (total bilirubin [TB] ≤1 mg/dL and ALT <35 U/L)
Study: 34310436
Drug: Partial resolution
Normalized name: Revolution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial resolution (TB >1 mg/dL and/or ALT >35 U/L)
Study: 34310436
Drug: GGT <100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GGT <100 U/L at baseline
Study: 34310835
Drug: Chemotherapy (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (1 to 5 courses)
Study: 34312462
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of mb-IL21 ex vivo expanded donor-derived NK cells
Study: 34312483
Drug: Anti-GITR neutralizing
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-GITR neutralizing antibodies
Study: 34312483
Drug: Accelerated radiation
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiation therapy
Study: 34312556
Drug: CAR19 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAR19 treatment
Study: 34465306
Drug: Weekly voluntary
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly voluntary screening for SARS-CoV-2 with a high sensitivity molecular-based saliva test
Study: 34314483
Drug: Danicopan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danicopan (100 to 200 mg thrice daily)
Study: 34315419
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (LB) 266 mg
Study: 34315767
Drug: Dilpacimab (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilpacimab (3.75 mg/kg)
Study: 34315767
Drug: Dilpacimab (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilpacimab (various doses 1.25-7.5 mg/kg)
Study: 34315767
Drug: Dilpacimab (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilpacimab (various doses)
Study: 34315793
Drug: Ripasudil 0.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ripasudil 0.4% eye drops administered once daily for 1 week, then two times per day for 2 weeks in phase I, and two times per day for 12 weeks in phase II.
Study: 34315821
Drug: Avelumab added
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab added to standard treatment
Study: 34315890
Drug: Treatment-related amenorrhea
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related amenorrhea (TRA)
Study: 34319245
Drug: Remote Patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote Patient Monitoring System (RPMS) for 3 months; includes a tablet, weight scale, and pedometer providing daily educational content, weekly weigh-ins.
Study: 34319435
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus cisplatin and 5-fluorouracil (TPF) induction chemotherapy
Study: 34319435
Drug: Surgery after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery after TPF chemotherapy
Study: 34319435
Drug: Radical concurrent
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical concurrent chemoradiotherapy after TPF chemotherapy
Study: 34319435
Drug: TPF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF chemotherapy alone
Study: 34319564
Drug: SNAC 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNAC 3.6 g
Study: 34320785
Drug: Temsirolimus (TEM)
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus (TEM) 25 mg weekly and Lenalidomide (LEN) 20 mg on days 1-21 every 28 days
Study: 34320949
Drug: Continuing secondary
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing secondary antibiotic prophylaxis
Study: 34320980
Drug: Systemic glucocorticoid
Normalized name: Glucocorticoids, Systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic glucocorticoid treatment (specific dosage and duration not mentioned)
Study: 34321280
Drug: Pexidartinib (600-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexidartinib (600-1000 mg daily) and Sirolimus (2-6 mg daily)
Study: 34321280
Drug: Pexidartinib and
Normalized name: pexidartinib
DrugBank: Pexidartinib (DB12978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pexidartinib and Sirolimus combination therapy
Study: 34321583
Drug: Regorafenib administered
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib administered for > 3 weeks
Study: 34321921
Drug: MPS-HA2% (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPS-HA2% (single injection)
Study: 34322164
Drug: Suprachoroidal injection
Normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprachoroidal injection of triamcinolone acetonide suspension (CLS-TA)
Study: 34322164
Drug: Systemic or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic or locally administered corticosteroids
Study: 34322775
Drug: Copanlisib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib (45 mg and 30 mg intravenously on days 1, 8, and 15 of 28-day cycles) in combination with cetuximab (standard doses of 400 mg/m weekly)
Study: 34323413
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of collagenase Clostridium histolyticum (CCH) at high doses (0.1-0.2 mg/cm)
Study: 34323413
Drug: Verteporfin and
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin and nintedanib (FDA-approved drugs)
Study: 34323955
Drug: Weekly isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly isoniazid and rifapentine (3HP) at standard doses (900 mg/week)
Study: 34323955
Drug: Weekly isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly isoniazid and rifapentine (3HP) in pregnant women with HIV
Study: 34323955
Drug: Weekly isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly isoniazid and rifapentine (3HP)
Study: 34323958
Drug: G-CHOP (Obinutuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CHOP (Obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Study: 34324028
Drug: Niraparib 300
Normalized name: niraparib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 300 mg single dose
Study: 34324028
Drug: Niraparib 200
Normalized name: niraparib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 200 mg daily (MHI)
Study: 34324028
Drug: Niraparib 200
Normalized name: niraparib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 200 mg or 300 mg based on weight and platelets (NHF)
Study: 34324392
Drug: Anti-CD7 CAR
Normalized name: Anti-CD7 CAR T-cell therapy
DrugBank: Anti-CD7 CAR T-cell therapy (DB18128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD7 CAR T cells, single infusion at a dose of 5 × 10
Study: 34324451
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) initiated in the first week of life
Study: 34325107
Drug: Neoadjuvant or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant or conversion chemotherapy
Study: 34326007
Drug: Phosphodiesterase type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase type 5 inhibitors (PDE5Is)
Study: 34327136
Drug: Penpulimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penpulimab (200 mg i.v. Q3W) plus Anlotinib (8 mg/day, 2 weeks on/1 week off)
Study: 34327344
Drug: Iguratimod (IGU)
Normalized name: dextromethorphan
DrugBank: Iguratimod (DB12233)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Iguratimod (IGU) 25 mg bid as monotherapy or to background therapy
Study: 34327344
Drug: Iguratimod (IGU)
Normalized name: dextromethorphan
DrugBank: Iguratimod (DB12233)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Iguratimod (IGU) 25 mg bid
Study: 34327406
Drug: Detachable string
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detachable string magnetically controlled capsule endoscopy (DS-MCCE)
Study: 34327510
Drug: Nonablative, Noncoagulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonablative, Noncoagulative Multipolar Radiofrequency and Pulsed Electromagnetic Field Treatment
Study: 34327561
Drug: dd-ABVD (dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: dd-ABVD (dose-dense ABVD)
Study: 34327604
Drug: Standardized Aronia
Normalized name: Aronia melanocarpa fruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized Aronia melanocarpa extract (SAE) 30 ml/day for 30 days
Study: 34329576
Drug: Venetoclax added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax added to CLIA (cladribine, high-dose cytarabine, idarubicin)
Study: 34329772
Drug: PRESERFLO® MicroShunt
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRESERFLO® MicroShunt with adjunctive use of topical mitomycin C (MMC; 0.2-0.4 mg/ml) for 2-3 minutes
Study: 34329772
Drug: PRESERFLO® MicroShunt
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRESERFLO® MicroShunt with adjunctive use of topical mitomycin C (MMC; 0.2 mg/ml)
Study: 34329772
Drug: PRESERFLO® MicroShunt
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRESERFLO® MicroShunt with adjunctive use of topical mitomycin C (MMC; 0.4 mg/ml)
Study: 34329846
Drug: Budigalimab 375
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budigalimab 375 mg via intravenous infusion every 3 weeks plus Rova-T 0.3 mg/kg intravenously on day 1 of the first and third 3-week cycle
Study: 34329939
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg b.i.d. + intravenous pegylated liposomal doxorubicin (PLD) 40 mg/m²
Study: 34329939
Drug: PLD 30
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 30 mg/m²
Study: 34330322
Drug: Paquinimod 3
Normalized name: Paquinimod
DrugBank: Paquinimod (DB13118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paquinimod 3 mg/day for 8 weeks
Study: 34330671
Drug: Radiofrequency (RF)
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency (RF) applications targeting the atrial edge of the leak, average 18 ± 7 RF applications per patient, mean maximum contact force 16 ± 3 g, mean power 44 ± 2 W, mean RF time 5.1 ± 2.5 minutes.
Study: 34330715
Drug: Surgical resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection after neoadjuvant treatment
Study: 34330766
Drug: Talimogene laherparepvec
Normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Talimogene laherparepvec (TVEC) with concurrent preoperative external beam radiation therapy (EBRT)
Study: 34330842
Drug: ASTX029, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASTX029, a dual-mechanism ERK inhibitor
Study: 34330906
Drug: ChAdOx1 Chik
Normalized name: CHIKUNGUNYA VACCINE
DrugBank: Chikungunya vaccine (live, attenuated) (DB18701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 Chik vaccine (single intramuscular injection at one of three preestablished dosages)
Study: 34330906
Drug: ChAdOx1 Chik
Normalized name: CHIKUNGUNYA VACCINE
DrugBank: Chikungunya vaccine (live, attenuated) (DB18701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 Chik vaccine (single intramuscular injection)
Study: 34330906
Drug: ChAdOx1 Chik
Normalized name: CHIKUNGUNYA VACCINE
DrugBank: Chikungunya vaccine (live, attenuated) (DB18701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 Chik vaccine
Study: 34330970
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drug (NSAID) intake
Study: 34331051
Drug: CoronaVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac vaccine in ARD group
Study: 34331111
Drug: Bortezomib in
Normalized name: bortezomib Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib in combination with fludarabine plus cyclophosphamide (B-FC)
Study: 34331589
Drug: Anamorelin 100
Normalized name: Anamorelin
DrugBank: Anamorelin (DB06645)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Anamorelin 100 mg orally daily with standardized physical activity and nutrition counseling for 43 days
Study: 34332992
Drug: Cap-based adjuvant
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap-based adjuvant chemotherapy
Study: 34333554
Drug: Lutetium-177 treatment
Normalized name: Lutetium-177
DrugBank: Lutetium Lu-177 (DB13982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutetium-177 treatment
Study: 34334250
Drug: p75 neurotrophin
Normalized name: neurotrophin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: p75 neurotrophin receptor intervention
Study: 34334342
Drug: InterStim implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: InterStim implant (de novo group)
Study: 34334342
Drug: InterStim implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: InterStim implant (replacement group)
Study: 34334342
Drug: InterStim implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: InterStim implant
Study: 34334713
Drug: Intravenous ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous ustekinumab
Study: 34335336
Drug: Web-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based intervention to promote positive mental health, details on dosage and duration not available.
Study: 34335465
Drug: Low-dose relacorilant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose relacorilant (100-200 mg/d) for 12 weeks
Study: 34335465
Drug: High-dose relacorilant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose relacorilant (250-400 mg/d) for 16 weeks
Study: 34335479
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning clustering based on AUCs of glucose and insulin during OGTT, and uric acid.
Study: 34336760
Drug: Patient-centered care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centered care and gentle approach to treatment
Study: 34339017
Drug: Proactive management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive management (PM) using calcipotriene 0.005%/betamethasone dipropionate 0.064% foam, twice-weekly during maintenance phase
Study: 34341142
Drug: anti-CD20 therapies
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-CD20 therapies
Study: 34341335
Drug: AZD1222 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1222 vaccine (one dose)
Study: 34341335
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with anti-CD38 monoclonal antibodies or belantamab mafodotin
Study: 34342593
Drug: Telehealth intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telehealth intervention focusing on hypoglycemia education and symptom monitoring, including initial in-person visit, 3 weekly telecoaching calls, 1 biweekly call, and final in-person visit over 8 weeks.
Study: 34343354
Drug: Tafasitamab 12
Normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tafasitamab 12 mg/kg weekly for up to four 28-day cycles
Study: 34344873
Drug: Radiolabeled epichaperome
Normalized name: Radiolabelled DUNP19
DrugBank: RAD 502 (DB17328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiolabeled epichaperome probe administered by intravenous injection (single microdose)
Study: 34346900
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy delivered via a smartphone mHealth app
Study: 34348724
Drug: Anticoagulant, antiaggregant,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant, antiaggregant, and anticoagulant plus antiaggregant drugs
Study: 34348889
Drug: electronically delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: electronically delivered cognitive behavioral therapy (e-CBT) for OCD, 16-week program
Study: 34348918
Drug: Manufacturer's recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufacturer's recommended threshold of 6 WHO U/mL
Study: 34348942
Drug: Stepwise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise treatment algorithm based on BFI score
Study: 34348942
Drug: Conventional laxatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional laxatives